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Summary A number of growth factors have been implicated in the control of the proliferation of breast
cancer cells and some have been reported to mediate the proliferative effects of oestradiol. MCF-7 cells were
treated with growth factors in the presence and absence of oestradiol. Oestradiol increased the response of
cells to the proliferative effects of epidermal growth factor (EGF), transforming growth factor alpha (TGF-M)
and basic fibroblast growth factor (bFGF). Platelet derived growth factor (PDGF) and cathepsin D had no
effect in the presence or absence of oestradiol while TGF-P slightly reduced the stimulation by oestradiol. In
the absence of oestradiol, there was little effect of combinations of growth factors although the effects of
bFGF and IGF-I were additive. In the presence of oestradiol, the effects of bFGF and TGF-a were additive
whereas bFGF acted as an IGF-I antagonist. Overall, bFGF had the greatest effect on cell proliferation
although this was less marked than the previously described effect of the IGFs and insulin. The effects of
oestradiol on the sensitivity of cells to the proliferative effects of bFGF did not appear to result from
regulation of bFGF receptor expression.
The factors which control the proliferation of breast cancer
cells are not well defined. Breast tumours express variable
levels of receptors for steroids (McGuire et al., 1975;
Osborne et al., 1980) and growth factors (Cullen et al., 1989)
and it has been proposed that the ligands for these receptors
act through a variety of autocrine and paracrine mechanisms.
Studies in vivo and in cell culture systems have implicated a
number of steroids and polypeptide growth factors (Lippman
et al., 1988) but the relative contribution of each growth
factor and the precise way in which each acts is not
known.
Breast cancer cell lines provide tractable experimental
systems for examining some aspects of the control of breast
cancer cell proliferation. Furthermore some cell lines such as
the MCF-7 cell line contain oestrogen receptors and their
proliferation is regulated by oestrogens (Lippman et al.,
1976; Johnson et al., 1989). They therefore provide useful
systems for studying the interactions between various growth
factors and for understanding the mechanisms involved in
the stimulation of proliferation by oestrogens and the
interactions between growth factors and steroids.
Transforming growth factors (TGFs), insulin-like growth
factors (IGFs), fibroblast growth factors (FGFs), platelet
derived growth factor (PDGF) and epidermal growth factor
(EGF) as well as other proteins such as cathepsin D have all
been implicated in the control of breast cancer cell prolifera-
tion. Some of these growth factors, such as PDGF, are
thought to be synthesised by tumour cells but to influence
breast cancer cell proliferation indirectly by regulating the
synthesis of other growth factors in stromal cells (Bronzert et
al., 1987). Other proteins, such as the transforming growth
factors (Bates et al., 1988; Knabbe et al., 1987) and cathepsin
D (Vignon et al., 1986) have been reported to be synthesised
by tumour cells and may act as autocrine mitogens. Regula-
tion of the synthesis of autocrine growth factors such as
TGF-a (Bates et al., 1988) and TGF-,B (Knabbe et al., 1987)
by oestrogens and antioestrogens has been reported and may
contribute to mediating the effects of oestrogens on breast
cancer cell proliferation.
The insulin-like growth factors are increasingly being im-
plicated in the control of the proliferation of a wide variety
of tumour cells (reviewed in Westley and May, 1991) and
these proliferative effects are generally thought to be medi-
ated through the type I IGF receptor. In some instances it
has been proposed that tumour cells respond to exogenous
IGFs, whereas in others such as small cell lung carcinoma,
there is well documented evidence that IGF-I functions as an
autocrine growth factor (Minuto et al., 1988). In breast
cancer, there is now a concensus that the cancer cells do not
produce biologically significant amounts of IGF-I (Yee et al.,
1991) although some appear to produce IGF-II (Osborne et
al., 1989). We have reported that oestrogens sensitise breast
cancer cells to the proliferative effects of IGFs (Stewart et al.,
1990) demonstrating that steroids can modulate the response
of breast cancer cells to growth factors. In this study we have
examined the effects of oestrogens on the response of breast
cancer cells to other growth factors. We conclude that modu-
lation of sensitivity does occur for other growth factors but
that the mechanisms involved may differ from those involved
for IGFs.
Materials and methods
Materials
Recombinant IGF-I and TGFa were obtained from Bachem
(UK). PDGF, bFGF and TGF-P1 were obtained from British
Biotechnology. EGF was obtained from Boehringer Mann-
heim. Bovine insulin was obtained from Collaborative
Research. Cathepsin D was purified from human spleen as
described previously (Reid et al., 1986).
Cell culture
MCF-7 cells were maintained in Dulbecco's Modified Eagles
medium supplemented with foetal calf serum (10%) and
porcine insulin (1 ;ig ml-1).
Growth experiments were performed as described
previously (Johnson et al., 1989). Cells (10,000) were plated
in 16-mm diameter wells in 0.5 ml and allowed to attach over
2 days. Prior to treatment, the cells were progressively with-
drawn from the oestrogens present in the normal growth
medium as described by Johnson et al. (1989). This involved
culturing the cells in phenol red-free modified Eagle's
medium supplemented with charcoal-treated newborn calf
serum (10%) and insulin (1 ,tgml-1) for 4 days. The medium
was changed twice daily for the first 3 days with a PBS wash
at every change. The cells were then cultured for a further 6
or 9 days in this medium which was supplemented with
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oestradiol and various combinations of growth factors. Cul-
ture medium was changed daily.
DNA assay
DNA was measured using bisbenzimidazole (Hoechst 33258)
as described previously (Johnson et al., 1989).
FGFbinding
FGF binding was measured essentially as described by Kan
et al. (1988). MCF-7 cells (20,000) were plated into 16 mm
wells in normal growth medium. When the cells were 40%
confluent, they were withdrawn from oestrogens present in
normal growth medium as described for the growth
experiments and then cells were treated with 10 nM oestradiol
for 2 days or cultured for a further 2 days in withdrawal
medium alone. Cell monolayers were washed with phosphate-
buffered saline containing 1 mg ml-I BSA (PBS/BSA) and
then incubated with varying concentrations of '25I-bFGF
(1,400 Ci mmol-', Amersham, UK) in the presence and
absence of a 100 fold molar excess of unlabelled bFGF in
binding buffer (PBS/BSA supplemented with 2 tgml1l
heparin) for 2 h on ice. The cells were then washed four times
with 0.5 ml of binding buffer and the bound '25I-bFGF was
then extracted by incubation with 1% triton X-100 for
15min on ice. The '25I-bFGF in the extraction buffer was
measured in a gamma counter. Total and non-specific bind-
ing was measured in triplicate.
cDNA hybridisation
Plasmids pDC115 and pCD116 containing cDNA correspond-
ing to the extracellular domains of the flg and bek FGF
receptors respectively (Dionne et al., 1990) were labelled with
32P-dCTP by random priming. MCF-7 cells were withdrawn
from oestrogens, and then treated for two days with oestra-
diol (10 nM) for 2 days as described above. Total RNA was
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extracted from control and oestrogen treated cells, electro-
phoresed on agarose gels containing 2.2 M formaldehyde and
transferred to nylon filters. The radiolabelled flg and bek
cDNA was then hybridised to the Northern transfers of
RNA for 72 h at 42°C as described by May and Westley
(1988).
All experiments were performed at least three times. In
general, each point is the mean of three measurements and
the bars represent the standard error of the mean.
Results
Modulation ofresponsiveness ofMCF-7 cells to growthfactors
by oestradiol
In the first series of experiments, growth factors which have
been implicated in the control of breast cancer cell prolifera-
tion were tested for their ability to stimulate the proliferation
of MCF-7 cells in the absence and presence of oestradiol.
Prior to treatment, cells were cultured in phenol red-free
medium containing charcoal-stripped serum. This medium
has been shown previously to contain extremely low levels of
oestrogen (May & Westley, 1988). After 5 days of culture in
this medium, cells stop proliferating thus permitting small
effects of added growth factors to be detected.
Under these culture conditions, oestradiol treatment
routinely resulted in a two-four fold increase in cell numbers
over 9 days. Addition of TGF-a or EGF alone (Figure la
and b) resulted in a small, but statistically significant increase
in cell numbers after 6 and 9 days of treatment. When cells
were treated with TGF-a and oestradiol (Figure la) or EGF
and oestradiol (Figure lb), the increase in cell numbers was
slightly greater than the sum of the increase observed in the
presence of oestradiol alone and the growth factor alone. The
increase in growth over 9 days was then measured at different
concentrations of TGF-o (Figure 2a) and EGF (Figure 2b).
The half-maximal increase was observed at 3 ng ml-l for
TGF-a in both the presence and absence of oestradiol. In the
MCF-7
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Figure 1 Stimulation of MCF-7 cell proliferation by TGF-z a, and EGF b, in the presence and absence of oestradiol. MCF-7 cells
were plated and withdrawn as described in the Materials and methods. In a, cells were cultured in withdrawal medium alone (0,
C), withdrawal medium supplemented with TGF-a (10 ngml-, *), oestradiol (10nm, 0 E2), or oestradiol and TGF-m together
(-, TGF-a + E2. In b, cells were cultured in withdrawal medium alone (0, C), withdrawal medium supplemented with EGF
(10 ngml-'), oestradiol alone (0, E2) or oestradiol and EGF together (U, EGF + E2). The number of cells was measured after 6
and 9 days and expressedc as a percentage of the number of cells in wells treated with oestradiol.642 A.J. STEWART et al.
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Figure 2 Dose response of the stimulation of MCF-7 cell proliferation by TGF-a a, and EGF b, in the presence and absence of
oestradiol. MCF-7 cells were plated and withdrawn as described in the Materials and methods. They were then cultured for 9 days
in withdrawal medium containing various concentrations of TGF-a a, or EGF b, in the presence (@) or absence (0) of oestradiol
(10 nM).
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Figure 3 Effect of cathepsin D a, and PDGF b, on MCF-7 cell proliferation in the presence and absence of oestradiol. MCF-7
cells were plated and withdrawn as described in the Materials and methods. In a, cells were cultured in withdrawal medium alone
(0, C), withdrawal medium supplemented with cathepsin D (5 ng ml-', 0, CD), oestradiol (1O nm, 0, E2) or cathepsin D and
oestradiol together (U, CD + E2). In b, cells were cultured in withdrawal medium alone (0, C), withdrawal medium supplemented
with PDGF (10 ng ml1, 0, PDGF), oestradiol alone (10 nm, 0, E2) or oestradiol together with PDGF (M, PDGF + E2). Cell
numbers were measured as described in the legend to Figure 1.
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presence of oestradiol, TGF-x increased cell proliferation 3
fold at concentrations of 10 gml-l and above but only 1.2
fold in the absence of oestradiol. For EGF half-maximal
stimulation was observed at a somewhat lower concentration
(1 ngml-') but the maximal stimulation was similar to that
observed for TGF-o.
Pro-cathepsin D has been reported to be mitogenic for
MGF-7 cells (Vignon et al., 1986). To test the mitogenic
activity of mature cathepsin D, MCF-7 cells were treated
with mature human cathepsin D purified from spleen. Figure
3a shows that there was no effect of cathepsin D (5 ng ml-1)
on proliferation in the presence or absence of oestradiol and
this was true for all concentrations tested (1, 5 and
50 ng ml-'). PDGF is a motogen which acts as a competence
factor for fibroblasts. The mitogenic activity of PDGF was
measured on MCF-7 cells in the presence and absence of
oestrogen. Figure 3b shows that PDGF had no effect on cell
proliferation and did not modulate the proliferative effect of
oestradiol at a concentration 1Ong ml-. PDGF was then
tested at a higher concentration (100 ng ml-') but again had
no effect on the proliferation of withdrawn or oestrogen-
treated MCF-7 cells.
Figure 4a and b show similar experiments with TGF-P and
bFGF respectively. TGF-P alone had no effect on cell pro-
liferation but marginally inhibited the stimulation of cell
proliferation induced by oestradiol. bFGF alone marginally
increased cell proliferation (1.4 fold) but treatment of MCF-7
cells with bFGF and oestradiol resulted in a significantly
greater stimulation (8.8 fold) of growth than obtained with
oestradiol alone (5 fold).
Effects ofcombinations ofgrowthfactors on MCF-7 cell
proliferation in the presence and absence ofoestradiol
Few studies have examined the effects of combinations of
growth factors on the proliferation of breast cancer cells and
none have studied the modulation of the effects of combina-
tions of growth factors by oestradiol.
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The growth inhibitory effect of TGF-0 on breast cancer
cell proliferation (Knabbe et al., 1987) has provoked much
interest. We have previously reported that insulin markedly
stimulates the proliferation of breast cancer cells in the
presence of oestradiol and we therefore examined whether
TGF-P could inhibit the large stimulation of proliferation
when MCF-7 cells are treated with insulin and oestradiol.
Figure 5 shows the dramatic synergism between oestradiol
and insulin. In this experiment, the stimulation by oestradiol
and insulin together was five fold that observed for oestradiol
alone. As in the experiment shown in Figure 4, TGF-P
marginally decreased oestrogen-induced proliferation but did
not reduce the much higher level of proliferation of cells
treated with insulin and oestradiol together.
Of the growth factors which stimulated the proliferation of
MCF-7 cells, TGF-a, EGF and bFGF (Figures 1-4) had the
most pronounced effects. TGF-o and EGF had similar effects
on the proliferation of MCF-7 cells, are both thought to act
through the EGF receptor and are therefore unlikely to have
an additive effect. However, as TGF- o and bFGF interact
with different receptors, the effects of TGF-x together with
bFGF were measured in the absence and presence of oestra-
diol. In the absence of oestradiol, both growth factors had
little effect either alone or in combination (Figure 6a). In the
presence of oestradiol, however, treatment ofcells with TGF-
a and bFGF resulted in a greater stimulation of proliferation
(8.5 fold) than with either growth factor alone (Figure 6b).
This experiment emphasised the dependence of the activity of
these two growth factors on the presence of oestradiol and
showed that they could also have additive effects in the
presence of oestradiol.
Finally, the interaction between IGF-I and FGF was
measured in the absence and presence of oestradiol to deter-
mine if bFGF could increase the proliferation stimulated by
IGF-I. In the absence of oestradiol, neither IGF-I nor bFGF
significantly increased cell proliferation but IGF-I and bFGF
increased cell numbers two-fold after 9 days of treatment
(Figure 7a). In the presence of oestradiol, however, bFGF
MCF-7
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Figure 4 Effect of TGF-P a, and bFGF b, on MCF-7 cell proliferation in the presence and absence of oestradiol. MCF-7 cells
were plated and withdrawn as described in the Materials and methods. In a, cells were cultured in withdrawal medium alone (0,
C), withdrawal medium supplemented with TGF-P (10 ng ml-', 0, TGF P), oestradiol alone (10 nm, 0, E2). In b, cells were
cultured in withdrawal medium alone (0, C), withdrawal medium supplemented with bFGF (10ngml-', 0, bFGF), oestradiol
alone (10 nm, 0, E2) or oestradiol together with bFGF (U, bFGF + E2). Cell numbers were measured as described in the legend to
Figure 1.644 A.J. STEWART et al.
inhibited the effects of IGF-I so that the number ofcells after
9 days of treatment was similar to that following treatment
with bFGF in the presence of oestradiol (Figure 7b).
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Figure 5 Effect of TGF-P on MCF-7 cell proliferation
stimulated by oestradiol and insulin. MCF-7 cells were plated
and withdrawn as described in Materials and methods. Cells were
cultered in withdrawal medium alone c, withdrawal medium
supplemented with oestradiol (1OnM, E2), insulin (1 Lg ml-) or
oestradiol and insulin in the presence (solid) or absence (open) of
TGF B (1O ng ml- ). Cell numbers were measured as described in
the legend to Figure 1.
The concentrations of bFGF which were synergistic with
oestradiol and which inhibited the effect of IGF-I in the
presence of oestradiol were defined by culturing MCF-7 cells
in the presence of various concentrations of bFGF with
oestradiol alone or IGF-I together with oestradiol (Figure 8).
Both effects of bFGF were dose dependent and were max-
imal at lOOpgml1'. However, significant antagonist effects
were observed at 1 and 10 pg ml1' whereas no agonist effects
were observed at this concentration. Half maximal stimula-
tion in the presence of oestradiol alone was observed at 30 pg
while half maximal inhibition in the presence of oestradiol
and IGF-I occurred at 7pg bFGF.
Characterisation ofbFGFbinding to MCF-7 cells
bFGF had the clearest synergistic effect of the growth factors
used in this study. We have previously reported that oestra-
diol increases expression of the type I IGF receptor on
MCF-7 cells (Stewart et al., 1990) and this may account for
the synergism between oestradiol and the IGFs. The effect of
oestradiol on bFGF binding was therefore measured. High
affinity binding of bFGF was measured as described in the
Materials and methods. Specific bFGF binding accounted for
approximately 60% of total binding as judged by the sup-
pression of '251I-bFGF binding by an excess (100 fold) of
unlabelled bFGF. Figure 9a shows binding curves of 125IJ
bFGF to withdrawn and oestrogen treated MCF-7 cells and
Figure 9b Scatchard plots of this data. The Scatchard plot is
consistent with a single class of binding sites and there was
no difference between the number of binding sites (9,600
sites/cell) or their affinity (0.6 nM) in withdrawn and oes-
trogen treated cells suggesting that expression of bFGF
receptors is not regulated by oestrogen.
The expression of two FGF receptors (flg and bek) was
then examined. cDNA corresponding to the extracellular
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Figure 6 Effect of oestradiol on MCF-7 cell proliferation stimulated by TGF-x and bFGF together. MCF-7 cells were plated and
withdrawn as described in the Materials and methods. In a, cells were cultured in withdrawal medium alone (0, C), or withdrawal
medium supplemented with TGF-a (10 ngml', A, TGF-a), bFGF (10 ng ml-', V, bFGF) or TGF-a and bFGF together (*,
bFGF + TGF-a). In b, cells were cultured in withdrawal medium supplemented with oestradiol (0, E2 alone) or oestradiol together
with TGE-c (10 ngml', A, + TGF-a), bFGF (10 ngml', V, + bFGF) or TGF-a and bFGF (*, + bFGF + TGF-a). Cell
numbers were measured as described in the legend to Figure 1.
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Figure 7 Effect of oestradiol on MCF-7 cell proliferation stimulated by IGF-I and bFGF together. MCF-7 cells were plated and
withdrawn as described in the Materials and methods. In a, cells were cultured in withdrawal medium alone (0, C), withdrawal
medium supplemented with IGF-I (50ngml1', V, IGF-I), bFGF (1Ongml-', A, bFGF) or IGF-I and bFGF together (*,
IGF-I + bFGF). In b, cells were cultured in withdrawal medium supplemented with oestradiol (10 nmml-', A, + bFGF), IGF-I
(50 ngml1', V, + IGF-I) or bFGF and IGF-I (*, + IGF-I + bFGF). Cell numbers were measured as described in the legend to
Figure 1.
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Figure 8 Effect of bFGF on the proliferation of MCF-7 cell
proliferation stimulated by oestradiol and IGF-I. MCF-7 cells
were plated and withdrawn as described in the Materials and
methods. Cells were cultured for 9 days in withdrawal medium
alone (unhatched), withdrawal medium supplemented with oest-
radiol alone (10 nM), hatched), withdrawal medium supplemented
with oestradiol (10 nM) and the indicated concentration of bFGF
(0) or withdrawal medium supplemented with oestradiol (10
nM), IGF-I (50 ng ml- ') and the indicated concentration of
bFGF (M). Cell numbers were measured as described in the
legend to Figure 1.
domains of the two receptors was hybridised to Northern
transfers of RNA extracted from withdrawn and oestrogen-
treated MCF-7 cells. No hybridisation of the bek cDNA was
detected, however the flg cDNA hybridised to an RNA of
4.2 kb but this RNA was expressed at the same level in
withdrawn and oestrogen treated cells (Figure 10).
Discussion
Although there have been extensive studies on the effects of
growth factors on the proliferation of breast cancer cells as
well as on the production of growth factors by breast cancer
cells, there have been relatively few studies on the interaction
between steroids and growth factors. Given that oestrogens
are important in tumour development in vivo and that oestro-
gens may mediate their effects through growth factor path-
ways, this is an area of some importance.
The analysis of the effects of oestrogens on breast cancer
cells has been facilitated by the development of oestrogen-
free culture conditions and the withdrawal of cells from
oestrogens present in normal culture media prior to treat-
ment. This involves the use of phenol-red free medium
supplemented with stripped serum and a withdrawal period
which involves frequent changes of medium to remove the
influences of steroids present in normal growth medium.
These culture conditions have been used to identify oestrogen
regulated mRNAs in breast cancer cells (May & Westley,
1988) and to study the effects of antioestrogens on the ex-
pression of oestrogen regulated genes (Johnson et al.,
1989).
We have previously reported that oestrogens sensitise three
oestrogen responsive breast cancer cell lines to the pro-
liferative effects of IGFs (Stewart et al., 1990). In the present
study we have examined the ability of oestrogen to modulate646 A.J. STEWART et al.
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Figure 9 Effect of oestradiol on binding of 1251-bFGF to MCF-7 cells. MCF-7 cells were plated and withdrawn as described in the
Materials and methods and then cultured in the presence (@) or absence (0) of oestradiol (10 nM) for 2 days. Cells were then
incubated with various concentrations of '25I-bFGF in the presence and absence of excess unlabelled bFGF and the amount of
specifically bound 1251-bFGF measured as described in the Materials and methods. Binding curves are shown in a, and Scatchard
plots of this data in b.
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Figure 10 Expression of FGF receptors flg and bek in MCF-7
cells. MCF-7 cells were withdrawn and then cultured in with-
drawal medium (C) or withdrawal medium containing oestradiol
(E2) for 2 days. 32P-labelled flg and bek cDNA was then hyb-
ridised to Northern transfers of RNA (10 gAg) extracted from
these cells. The size of the RNA which hybridised to theflg probe
(4,200 nucleotides) is marked.
the sensitivity of MCF-7 cells to the proliferative activity of
other growth factors implicated in the control of breast
cancer cell proliferation. Experiments were also performed on
the oestrogen responsive T47D cell line and although the
magnitude of the effects varied in the two cell lines,
qualitatively similar results were obtained suggesting that
sensitisation to growth factors by oestrogen is a general
phenomenum.
TGF-P, cathepsin D and PDGF had little effect on growth
either in the presence or absence of oestradiol. TGF-1 has
been reported by others to inhibit the proliferation of several
breast cancer cell lines including MCF-7 (Knabbe et al.,
1987). In this study, control cells do not proliferate and an
inhibitory effect of TGF-P on these cells would not therefore
be expected. The small inhibitory effect of TGF-P on oestro-
gen stimulated growth was more surprising. Although it has
been reported that TGF-P inhibits the proliferation of MCF-
7 cells, no studies have demonstrated that TGF-P inhibits
oestrogen stimulated proliferation under conditions where
untreated cells do not proliferate. It is possible, therefore,
that TGF-P predominantly inhibits proliferation resulting
from the action of other growth factors present in the serum.
Arteaga et al. (1988) have reported that oestrogen receptor
positive cell lines are not inhibited by TGF-P and our data
are therefore largely consistent with this study. The lack of
an effect of PDGF is in agreement with other studies using
somewhat different culture conditions (Karey & Sirbasku,
1988; Bronzert et al., 1987) and is consistent with the inabi-
lity to detect receptors for PDGF on MCF-7 cells. The lack
of effect of cathepsin D in the presence and absence of
oestradiol is in agreement with the data of Karey and Sir-
basku (1988). A stimulation of growth by purified procathep-
sin D has, however, been reported for MCF-7 cells (Vignon
et al., 1986).
EGF and TGF-(x alone both stimulated cell proliferation
considerably less than did oestradiol alone. This suggests that
addition of TGF-a to the culture medium cannot substitute
for oestradiol and this argues that the induction of TGF-a
cannot be responsible for mediating all the effects of oestra-
diol on cell proliferation as was proposed by Bates et al.
(1988). Furthermore, proliferation in the presence of TGF-xc
or EGF and oestradiol was actually greater than in the
presence of oestradiol alone and this is not consistent with
either growth factor acting as an oestrogen-induced autocrine
growth factor. Experiments with transfected cell lines which
express high levels of TGF-x constitutively but which retain
oestrogen responsiveness (Clarke et al., 1989), and the
identification of an oestrogen responsive cell line which does
not express epidermal growth factor receptor which mediates
the effects of TGF-x (Leung et al., 1987), have also suggested
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that TGF-a plays a relatively minor role as an oestrogen
induced autocrine mitogen and are consistent with our
data.
Although the cooperative effects of growth factors on the
proliferation of cells such as fibroblasts is well documented
and has given rise to the concept of competence and progres-
sion factors, the interaction of growth factors in the control
of the proliferation of breast cancer cells is poorly under-
stood.
bFGF was first reported to act as a mitogen for breast
cancer cells by Karey and Sirbasku (1988) although it had
previously been shown to stimulate the growth of rat mam-
mary myoepithelial and stromal cell lines (Rudland et al.,
1977; Smith et al., 1984). In this study, bFGF alone increased
cell numbers to a limited extent in the absence of oestradiol
but in contrast to the other growth factors tested, bFGF
acted synergistically with oestradiol. This effect is similar to,
though not as dramatic as, the synergism observed previously
between oestradiol and the IGFs (Stewart et al., 1990). We
have suggested that oestrogens sensitise breast cancer cells to
the mitogenic effects of IGFs and have shown that oestrogen
stimulated cells express more type I IGF receptor on the cell
surface which may account for the increased response to
IGFs (Stewart et al., 1990). The situation with FGF recep-
tors appears to be different. FGF binding was detected on
MCF-7 cells but was not increased by oestrogens. The syner-
gism between oestrogens and bFGF could therefore result
from an effect of oestrogen on the post-receptor signal trans-
duction pathway or even an effect of bFGF on components
of the oestrogen receptor pathway.
In this study, the interaction of bFGF with TGF-o and
IGF-I were studied as these three growth factors had the
most significant effects on the proliferation of MCF-7 breast
cancer cells. Interestingly, the effects observed depended on
the combination of growth factors and the presence of oes-
tradiol. In the absence of oestradiol, TGF-a and bFGF had
little effect either singly or in combination whereas in the
presence of oestradiol the much larger effects of these two
growth factors were additive and together gave rise to a large
stimulation in cell numbers. This contrasted with the results
obtained when IGF-I and bFGF were combined. In the
absence of oestradiol, the effects of IGF-I and bFGF were
additive whereas in the presence of oestradiol, bFGF
appeared to act as an IGF-I antagonist. There are few
reports of bFGF inhibiting cell growth although Kan et al.
(1988) have reported that bFGF inhibits the growth of a
hepatoma cell line and this has been linked to the expression
of a class oflow affinity FGF receptors on the cell surface. In
MCF-7 cells, a higher concentration of bFGF was required
to stimulate proliferation in the presence of oestradiol alone
than was required to inhibit the proliferation stimulated by
oestradiol and IGF-I together. It is possible that in this case,
the agonist and antagonist effects of bFGF may be mediated
by two different receptors and that oestrogen and IGFs
modulate the transmission of positive and negative signals
from these different receptors.
The experiments described in this study have demonstrated
that the response of cells to growth factors can be modulated
by steroids and other growth factors. Clearly the situation in
breast tumours is complex because of the presence of multi-
ple cell types and because breast tumours from different
individuals can express widely varying levels of a variety of
growth factors and their receptors. However, experiments
such as those described in this study using cultured breast
cancer cells should help to identify the growth factors and
signal transduction systems which exert the greatest influence
on breast cancer cell proliferation and may ultimately help to
identify novel therapeutic targets for breast cancer treat-
ment.
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